How
LARTRUVO
May
Help

IN SOFT TISSUE SARCOMA:

THE FIRST SIGNIFICANT FRONT-LINE ADVANCEMENT IN MORE THAN 40 YEARS

WHO IS LARTRUVO FOR?

LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who cannot be cured with radiation or surgery.

There is an ongoing study to confirm how LARTRUVO works in combination with doxorubicin.

Start with LARTRUVO:

Ask your doctor if starting LARTRUVO + doxorubicin is right for you

CLINICAL TRIAL RESULTS

LARTRUVO may help you live longer

LARTRUVO in combination with doxorubicin (a type of chemotherapy) helped people live significantly longer than those who took doxorubicin alone

LIVED NEARLY 2 TIMES LONGER

In a study, people who were treated with LARTRUVO + doxorubicin lived nearly twice as long as those who were treated with doxorubicin alone.

Half of the patients who received LARTRUVO + doxorubicin (66 people) were still alive at 26.5 months compared to 14.7 months with doxorubicin alone (67 people). This is a measure of how well a treatment works, which is called median overall survival.

SLOWS THE PROGRESSION OF DISEASE

Patients receiving LARTRUVO + doxorubicin (66 people) lived without their cancer getting worse for 8.2 months versus 4.4 months with doxorubicin alone (67 people).

2 TIMES AS MANY PEOPLE EXPERIENCED TUMOR SHRINKAGE

Twice as many people had their tumors shrink with LARTRUVO + doxorubicin (18.2% of 66 patients) than with doxorubicin alone (7.5% of 67 patients).

LARTRUVO may not work for everyone. Individual results from treatment may vary.

STUDY DETAILS

A clinical study included people with more than 20 different subtypes of soft tissue sarcoma. They received either LARTRUVO with doxorubicin or doxorubicin alone. There were 133 people in the study.

The study assessed overall survival, which is how long people lived after starting treatment. The trial also measured the length of time that tumors didn’t grow, spread, or worsen after starting treatment (progression-free survival) and the proportion of people whose tumors shrank (objective response rate).

LARTRUVO was studied in many different subtypes.*

Talk to your healthcare team if you have questions regarding your specific subtype.

*Specific clinical benefits for each subtype have not been established.

HOW LARTRUVO WAS GIVEN IN THE STUDY

In the study, people were assigned to one of 2 groups that each received a different medication regimen:

Group 1: 66 people treated with LARTRUVO + doxorubicin (a type of chemotherapy)

Group 2: 67 people treated with doxorubicin alone

People in the study were eligible to receive treatment with anthracycline, such as the chemotherapy doxorubicin. People in the study were not eligible for curative treatment.

HOW LARTRUVO
WORKS

LARTRUVO works differently than a chemotherapy. It is a monoclonal antibody, a type of biologic therapy that works to mimic part of your body’s own immune system. LARTRUVO binds to certain substances and blocks cells from sending growth signals to cancer cells, as well as healthy cells.

POSSIBLE SIDE EFFECTS OF LARTRUVO

  • The most common side effects of LARTRUVO include:

    • Nausea

    • Tiredness or weakness

    • Pain in the muscles, joints,
      and bones

    • Sores and swelling of the
      mouth and digestive tract

    • Hair loss

    • Vomiting

    • Diarrhea

    • Decreased appetite

    • Stomach pain

    • Weakness, numbness, or pain in the
      hands and feet

    • Headache

This is not a full list of side effects

Talk to your healthcare team if you notice side effects, including any signs of fever.

You are encouraged to report negative
side effects of prescription drugs to the FDA.
Visit www.fda.gov/safety/medwatch or call
1-800-FDA-1088.

HAVE A QUESTION?

  • You probably have questions about your treatment with LARTRUVO. Always talk with your doctor first if you have any questions or if you are seeking medical advice. Your personal healthcare team is the best source of information about your health

  • If you have any questions about LARTRUVO, you can give us a call at The Lilly Answers Center: 1-800-LILLYRX (1-800-545-5979)

    • By calling this number, you will have access to a Lilly representative who can provide additional information. The toll-free number is a service provided by Eli Lilly and Company and is not intended to replace the advice of your healthcare team

  • If you have a medical emergency, immediately call 911 or your local emergency services number

x

INDICATION AND IMPORTANT SAFETY INFORMATION

EXPAND

WHO IS LARTRUVO FOR?

LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who cannot be cured with radiation or surgery.

There is an ongoing study to confirm how LARTRUVO works in combination with doxorubicin.

IMPORTANT SAFETY INFORMATION FOR LARTRUVO

What is the most important information I should know about LARTRUVO?

  • Infusion reactions related to injecting LARTRUVO have occurred. Most of these reactions happened during or after the first or second LARTRUVO infusion. Signs and symptoms of infusion reactions include flushing, shortness of breath, severe trouble breathing, or fever/chills. In severe cases, severe low blood pressure, anaphylactic shock (a severe, potentially life-threatening allergic reaction), or cardiac arrest (abrupt loss of heart function) may occur. Tell your doctor if you have any of these symptoms. Your healthcare team will monitor you for these side effects. In the case of a severe infusion reaction, your LARTRUVO treatment will have to be immediately and permanently stopped.

  • LARTRUVO can harm your unborn baby. You should avoid getting pregnant, and use effective birth control while receiving LARTRUVO and for at least 3 months after stopping LARTRUVO.

What are the most common side effects of LARTRUVO?

  • The most common side effects reported in patients treated with LARTRUVO when given in combination with doxorubicin were nausea; tiredness or weakness; pain in the muscles, joints, and bones; sores and swelling of the mouth and digestive tract; hair loss; vomiting; diarrhea; decreased appetite; stomach pain; weakness, numbness, or pain in the hands and feet; and headache.

  • The most common changes to blood tests were low white blood cell count, low platelet count, high blood sugar, increased blood clotting time, low blood potassium level, and low blood phosphate level.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch or call 1-800-FDA-1088.

What should I tell my doctor before receiving treatment with LARTRUVO?

Before you receive LARTRUVO, tell your doctor if you:

  • Are pregnant or may be pregnant. If you become pregnant during treatment, discuss this with your doctor.

  • Are breastfeeding: your doctor will tell you not to breastfeed during LARTRUVO treatment and for at least 3 months after stopping LARTRUVO.

Tell your doctor about all the medications you are taking, including prescription and over-the-counter medications.

LARTRUVO is available by prescription only.

Please see full Prescribing Information for additional information about LARTRUVO.

OR CON ISI 12JAN2017

WHO IS LARTRUVO FOR?

LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who cannot be cured with radiation or surgery.

There is an ongoing study to confirm how LARTRUVO works in combination with doxorubicin.

IMPORTANT SAFETY INFORMATION FOR LARTRUVO

What is the most important information I should know about LARTRUVO?

  • Infusion reactions related to injecting LARTRUVO have occurred. Most of these reactions happened during or after the first or second LARTRUVO infusion. Signs and symptoms of infusion reactions include flushing, shortness of breath, severe trouble breathing, or fever/chills. In severe cases, severe low blood pressure, anaphylactic shock (a severe, potentially life-threatening allergic reaction), or cardiac arrest (abrupt loss of heart function) may occur. Tell your doctor if you have any of these symptoms. Your healthcare team will monitor you for these side effects. In the case of a severe infusion reaction, your LARTRUVO treatment will have to be immediately and permanently stopped.

  • LARTRUVO can harm your unborn baby. You should avoid getting pregnant, and use effective birth control while receiving LARTRUVO and for at least 3 months after stopping LARTRUVO.

What are the most common side effects of LARTRUVO?

  • The most common side effects reported in patients treated with LARTRUVO when given in combination with doxorubicin were nausea; tiredness or weakness; pain in the muscles, joints, and bones; sores and swelling of the mouth and digestive tract; hair loss; vomiting; diarrhea; decreased appetite; stomach pain; weakness, numbness, or pain in the hands and feet; and headache.

  • The most common changes to blood tests were low white blood cell count, low platelet count, high blood sugar, increased blood clotting time, low blood potassium level, and low blood phosphate level.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch or call 1-800-FDA-1088.

What should I tell my doctor before receiving treatment with LARTRUVO?

Before you receive LARTRUVO, tell your doctor if you:

  • Are pregnant or may be pregnant. If you become pregnant during treatment, discuss this with your doctor.

  • Are breastfeeding: your doctor will tell you not to breastfeed during LARTRUVO treatment and for at least 3 months after stopping LARTRUVO.

Tell your doctor about all the medications you are taking, including prescription and over-the-counter medications.

LARTRUVO is available by prescription only.

Please see full Prescribing Information for additional information about LARTRUVO.

OR CON ISI 12JAN2017

X

You are now leaving the www.LARTRUVO.com website.

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC, does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC, is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

  • Continue

  • Cancel

X

For US Healthcare Professionals

The information contained in www.LARTRUVO.com/hcp is technical in nature and intended for healthcare professionals in the United States only.

I'd like information for:

  • Healthcare Professionals

  • Patients and Caregivers